Navigating CNS Effects and Treatment Strategies in NSCLC

This chapter focuses on managing central nervous system side effects and suicidal ideation in patients receiving ALK inhibitors for non-small cell lung cancer. It covers strategies for handling disease progression during and after electinib treatment, emphasizing different treatments while stressing the importance of ongoing surveillance for brain metastases. The discussion also highlights ongoing research into overcoming resistance mutations and the complexities of clinical trials in this area.